Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Two months after he received a gene-edited pig heart, David Bennett Sr. has died. He was 57.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
Solve FSHD exists to fund biotechnology and biopharmaceutical research and development efforts toward finding a treatment and cure for FSHD.
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
Before next-generation metabolomics becomes mainstream, the medical establishment needs to expand its mindset around cancer and translate this understanding into the clinic.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
Bristol Myers Squibb’s moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals’ generic version, lenalidomide.